Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
68.71%
Operating Margin
14.77%
Net Margin
6.84%
Efficiency Metrics
Revenue per Expense Ratio
1.17
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
71.45%
Income Tax Rate
0.00%
EPS
0.2000000000
Balance Sheet Analysis
Current Ratio
0.11
Cash Ratio
0.06
Working Capital
$-203.10M
Debt to Equity
1.81
Debt to Assets
60.51%
Equity Ratio
33.50%
Cash Flow Analysis
Operating Cash Flow Ratio
40.97%
Free Cash Flow Ratio
23.58%
CapEx to Revenue
17.39%
Dividends Paid
$41.93M
Stock Buybacks
$48.89M
Total Shareholder Returns
$90.82M
Cash Position Change
-16.05%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
8.89%
Net Income
178.95%
EPS
146.51%
Operating Income
89.94%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-6.49%
Operating Cash Flow
13.35%
Free Cash Flow
389.26%
Balance Sheet Health
Assets
-5.22%
Debt
-4.81%
Book Value per Share
-14.77%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-4.18%
Shares Outstanding
9.49%
Long Term Trends
3Y Revenue/Share
-23.22%
5Y Revenue/Share
-55.05%
3Y Dividend/Share
-31.16%
5Y Dividend/Share
-58.11%